TC BioPharm shares are trading higher after the company announced the execution of a non-binding letter of intent to acquire a company pursuing the development of innovative CAR-T therapies for the treatment of refractory cancers and solid tumors.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.